Tim Cooksley1, Geraldine Campbell2, Tamer Al-Sayed2, Lisa LaMola3, Richard Berman3. 1. Department of Acute Medicine and Critical Care, The Christie, Wilmslow Road, Manchester, UK. cooks199@hotmail.com. 2. Department of Acute Medicine and Critical Care, The Christie, Wilmslow Road, Manchester, UK. 3. Department of Supportive Care, The Christie, Wilmslow Road, Manchester, UK.
Abstract
PURPOSE: Outpatient management of low risk febrile neutropenia patients (LRFN) identified by the MASCC score is a safe and effective strategy. Early supportive care has been shown to improve outcomes in patients with care. We developed an innovative ambulatory outpatient "enhanced supportive care" (ESC) clinic combining emergency oncology and supportive care through which we incorporated the management of patients with LRFN. METHODS: An ESC clinic was started in January 2017 at a tertiary cancer hospital in the North West of England. An integral part of the clinic was an ambulatory pathway for patients presenting with LRFN. Patients with a MASCC score ≥ 21 and an Early Warning Score ≤ 3 were potentially eligible for the pathway. Suitable patients were managed with oral amoxicillin/clavulanic acid (500/125 mg TDS) and ciprofloxacin (500 mg BD) or moxifloxacin 400 mg OD if penicillin allergic. All patients had one dose of intravenous meropenem on arrival. RESULTS: In its first year, 68 patients with LRFN were managed through the clinic. Table 1 shows the demographic data of the patients. Six (8.8%) patients had a 7-day readmission. There were no serious complications in the cohort. CONCLUSION: The ESC clinic maybe an effective method for delivering outpatient ambulatory management of patients with LRFN.
PURPOSE:Outpatient management of low risk febrile neutropeniapatients (LRFN) identified by the MASCC score is a safe and effective strategy. Early supportive care has been shown to improve outcomes in patients with care. We developed an innovative ambulatory outpatient "enhanced supportive care" (ESC) clinic combining emergency oncology and supportive care through which we incorporated the management of patients with LRFN. METHODS: An ESC clinic was started in January 2017 at a tertiary cancer hospital in the North West of England. An integral part of the clinic was an ambulatory pathway for patients presenting with LRFN. Patients with a MASCC score ≥ 21 and an Early Warning Score ≤ 3 were potentially eligible for the pathway. Suitable patients were managed with oral amoxicillin/clavulanic acid (500/125 mg TDS) and ciprofloxacin (500 mg BD) or moxifloxacin 400 mg OD if penicillinallergic. All patients had one dose of intravenous meropenem on arrival. RESULTS: In its first year, 68 patients with LRFN were managed through the clinic. Table 1 shows the demographic data of the patients. Six (8.8%) patients had a 7-day readmission. There were no serious complications in the cohort. CONCLUSION: The ESC clinic maybe an effective method for delivering outpatient ambulatory management of patients with LRFN.
Entities:
Keywords:
Ambulatory; Febrile neutropenia; Low risk; MASCC; Supportive care
Authors: Jennifer S Temel; Joseph A Greer; Alona Muzikansky; Emily R Gallagher; Sonal Admane; Vicki A Jackson; Constance M Dahlin; Craig D Blinderman; Juliet Jacobsen; William F Pirl; J Andrew Billings; Thomas J Lynch Journal: N Engl J Med Date: 2010-08-19 Impact factor: 91.245
Authors: J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott Journal: J Clin Oncol Date: 2000-08 Impact factor: 44.544
Authors: Benjamin W Teh; Christine Brown; Trish Joyce; Leon J Worth; Monica A Slavin; Karin A Thursky Journal: Support Care Cancer Date: 2017-10-10 Impact factor: 3.603
Authors: Tim Cooksley; Carme Font; Florian Scotte; Carmen Escalante; Leslie Johnson; Ronald Anderson; Bernardo Rapoport Journal: Support Care Cancer Date: 2020-11-23 Impact factor: 3.603
Authors: Jason J Bischof; Montika Bush; Rayad Bin Shams; Frances A Collichio; Timothy F Platts-Mills Journal: Support Care Cancer Date: 2021-06-05 Impact factor: 3.603
Authors: R Berman; A Davies; T Cooksley; R Gralla; L Carter; E Darlington; F Scotté; C Higham Journal: Clin Oncol (R Coll Radiol) Date: 2020-08-16 Impact factor: 4.126